Reuters Article: Barriers to Latest Alzheimer’s Treatments for Down Syndrome Community
Hampus Hillerstrom, CEO of LuMind IDSC Foundation and father to a child with Down syndrome, knows about the barriers people
October 10, 2023
Hampus Hillerstrom, CEO of LuMind IDSC Foundation and father to a child with Down syndrome, knows about the barriers people
Tuesday, September 26, 2023 NIH designates people with disabilities as a population with health disparities Designation, new research program and
Down syndrome leader Christina Reaves will lead community programs for LuMind IDSC Following a five-month, national search, LuMind IDSC Down
LuMind IDSC and The Arc of Northeast collaborated on an OpEd that was recently published in The Boston Globe. Authors
Medicaid Enrollment and Service Use Among Adults with Down Syndrome September 16, 2023 In a recently published study in the
Five takeaways for the Down syndrome community: Updates on accessing the new Alzheimer’s drugsLuMind IDSC is working on many levels
LuMind IDSC issues statement following FDA full approval of Leqembi™ to treat early-stage Alzheimer’s disease July 7, 2023 In a
Last week the FDA announced a full approval of a new drug called Leqembi to treat Alzheimer’s Disease. The approval
Seeking to rectify existing federal and state policies which prevent people with intellectual disabilities from accessing new therapies for Alzheimer’s
An international group of experts convened to determine prescribing criteria equivalences that would be inclusionary of adults with Down syndrome.